Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.3.1.28 (
chloramphenicol acetyltransferase
)
5,100
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
AP-2 is a retinoic acid-inducible and developmentally regulated activator of transcription. We have cloned an alternative AP-2 transcript (
AP-2B
) from the human teratocarcinoma cell line PA-1, which encodes a protein differing in the C terminus from the previously isolated AP-2 protein (AP-2A). This protein contains the activation domain of AP-2 and part of the DNA binding domain but lacks the dimerization domain which is necessary for DNA binding. Analysis of overlapping genomic clones spanning the entire AP-2 gene proves that AP-2A and
AP-2B
transcripts are alternatively spliced from the same gene. Both transient and stable transfection experiments show that
AP-2B
inhibits AP-2 transactivator function, as measured by an AP-2-responsive
chloramphenicol acetyltransferase
reporter plasmid. Furthermore, constitutive
AP-2B
expression in PA-1 cells causes a retinoic acid-resistant phenotype, anchorage-independent growth in soft agar, and tumorigenicity in nude mice, in a fashion similar to transformation of these cells by oncogenes. To determine the mechanism by which
AP-2B
exerts its inhibitory function, we purified bacterially expressed AP-2A and
AP-2B
proteins. While bacterial
AP-2B
does not bind an AP-2 consensus site, it strongly inhibits binding of the endogenous AP-2 present in PA-1 cell nuclear extracts. However, DNA sequence-specific binding of bacterially expressed AP-2A cannot be inhibited by bacterially expressed
AP-2B
. Therefore, inhibition of AP-2 activity by the protein
AP-2B
may require an additional factor or modification supplied by nuclear extracts.
...
PMID:An alternatively spliced mRNA from the AP-2 gene encodes a negative regulator of transcriptional activation by AP-2. 832 Dec 21